No benefit of 3,4-diaminopyridine in essential tremor: a placebo-controlled crossover study.
3,4-Diaminopyridine (3,4-DAP) is a potassium channel blocker that has recently demonstrated an antioscillatory effect in humans by significantly reducing downbeat nystagmus. Based on the presumed role of intrinsic oscillations in the pathophysiology of essential tremor (ET), the authors conducted a double-blind, placebo-controlled crossover study assessing the antitremor effect of a single dose of 3,4-DAP in 19 patients with ET. They did not find any significant change in tremor severity as measured by clinical ratings or accelerometry.
Lorenz
D
D
Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.
Hagen
K
K
Ufer
M
M
Cascorbi
I
I
Deuschl
G
G
Volkmann
J
J
D015761:4-Aminopyridine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D000077770:Amifampridine; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D020329:Essential Tremor / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D015990:Placebo Effect; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects; D012720:Severity of Illness Index; D017211:Treatment Failure
D026902:Potassium Channel Blockers; D015761:4-Aminopyridine; D000077770:Amifampridine